The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

About 15% of colon cancers are dMMR, which confers resistance to chemotherapy. ICIs have FDA approval for metastatic dMMR ...

Researchers at ASCO reviewing data from the ATOMIC trial said they will change practice based on the results but questioned ...

Adding atezolizumab to standard adjuvant chemotherapy significantly delayed recurrence or death for individuals with stage ...

Adding atezolizumab to chemo in stage 3 dMMR colon cancer halves the risk of recurrence, marking a major step in precision ...

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The Alliance for Clinical Trials in Oncology has announced results from ATOMIC, a Phase III trial evaluating standard ...

Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant ...